The national provisions on the obligation to report the adverse reactions of medicinal products notified to the Commission by the Federal Republic of Germany by letter of 18 January 2001, and which derogate from Directive 2000/38/EC are rejected.
資料由法律人 LawPlayer整理提供·EU law / curated by LawPlayer from EUR-Lex
2001/571/EC: Commission Decision of 18 July 2001 on the national provisions notified by Germany in the field of pharmacovigilance (Text with EEA relevance) (notified under document number C(2001) 1974)
This Decision is addressed to the Federal Republic of Germany.
Done at Brussels, 18 July 2001.
For the Commission
Erkki Liikanen
Member of the Commission
(1) OJ L 147, 9.6.1975, p. 13.
(2) OJ L 139, 10.6.2000, p. 28; corrected in OJ L 249, 4.10.2000, p. 26 and in OJ L 262, 17.10.2000, p. 46.
(3) OJ L 214, 24.8.1993, p. 22.
(4) OJ L 214, 24.8.1993, p. 1.
(5) In the light of the corrigendum in OJ L 262, 10.7.2000, p. 46.
(6) BGBl. I p. 3586; as last amended by Article 2 of the Law of 20 July 2000, BGBl. I p. 1045.
(7) OJ C 130, 1.5.2001, p. 2.
Cite this act
2001/571/EC: Commission Decision of 18 July 2001 on the national provisions notified by Germany in the field of pharmacovigilance (Text with EEA relevance) (notified under document number C(2001) 1974) (EUR-Lex). Retrieved via LawPlayer, https://lawplayer.com/eu/act/32001D0571
© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.
本頁資料來源:EUR-Lex·整理提供:法律人 LawPlayer· lawplayer.com